Dianabol (Methandrostenolone)

Methandrostenolone is a modified testosterone molecule with c17-alpha alkylation (for oral bioavailability) and a C1-2 double bond (which reduces androgenic activity and alters estrogenic metabolism). It binds to the androgen receptor to promote protein synthesis, nitrogen retention, and glycogenolysis. Dianabol aromatizes at a moderate rate to methylestradiol, a potent estrogen. Additionally, it interacts directly with estrogen receptors independent of aromatization, which is why AI therapy alone may not fully control estrogenic sides. Dianabol strongly enhances glycogen storage in muscle tissue (glycogen supercompensation), contributing to the rapid weight gain and pronounced muscle fullness. It also increases intracellular calcium retention and inhibits cortisol binding, providing anti-catabolic effects.

Methandrostenolone is rapidly absorbed after oral administration with peak plasma levels within 1-3 hours. The c17-alpha alkylation provides oral bioavailability of approximately 90% while conferring hepatotoxicity. The short terminal half-life of 4-6 hours necessitates multiple daily dosing. Metabolism occurs primarily in the liver via 6-beta hydroxylation and conjugation. The short half-life means the compound clears the system rapidly after cessation, with urinary metabolites detectable for 5-6 weeks. Despite the short half-life, the biological anabolic effects of each dose persist somewhat longer than the plasma presence due to nuclear receptor binding dynamics.

• ✓Extremely rapid mass gains (10-20 lbs in 4-6 weeks is common, including water)
• ✓Dramatic strength increases within the first 1-2 weeks
• ✓Strong nitrogen retention and glycogen supercompensation
• ✓Enhanced protein synthesis at a high rate
• ✓Improved sense of well-being and euphoria at moderate doses
• ✓Excellent "kickstart" compound while waiting for long-ester injectables to saturate
• ✓One of the most cost-effective AAS available
• ✓Strong synergy with testosterone and nandrolone for mass stacks

• ⚠Significant water retention and bloating from aromatization
• ⚠High hepatotoxicity (c17-alpha alkylated)
• ⚠Gynecomastia risk from estrogenic activity and direct interaction with estrogen receptor
• ⚠Elevated blood pressure from water retention and increased blood volume
• ⚠Severe suppression of natural testosterone production
• ⚠Negative impact on lipid profile
• ⚠Acne and oily skin
• ⚠Potential for significant weight loss post-cycle as water retention subsides

Contraindications

• 🚫Pre-existing liver disease or elevated liver enzymes
• 🚫Hypertension or cardiovascular disease
• 🚫History of or susceptibility to gynecomastia
• 🚫Severe dyslipidemia
• 🚫Kidney disease
• 🚫Concurrent use of other hepatotoxic substances
• 🚫Individuals who are sensitive to estrogen-related side effects
• 🚫Women (high virilization risk)

If used as a kickstart with long-ester injectables: No separate PCT needed; follow the PCT schedule for the injectable base. If used standalone: Begin PCT 1-2 days after last dose. Nolvadex 20mg/day for 6 weeks, or Clomid 50mg/day for 4 weeks. Estrogen rebound can occur post-Dianabol; consider continuing low-dose AI for 1-2 weeks after cessation. Liver support (TUDCA 500mg, NAC 1200mg) for 4 weeks after stopping.

• 1.Use Dianabol as a 4-6 week kickstart while waiting for long-ester injectables (Test E/C, Deca) to saturate
• 2.TUDCA (500mg/day) and NAC (1200mg/day) are non-negotiable liver support supplements during any Dbol cycle
• 3.Keep anastrozole dosed at 0.5mg EOD as a starting point and adjust based on estrogen symptoms and bloodwork
• 4.Monitor blood pressure daily; if systolic consistently exceeds 140, reduce dose or add a mild diuretic
• 5.Expect to lose 5-10 lbs of water weight in the 2 weeks after discontinuing Dianabol - this is normal and not muscle loss
• 6.The pre-workout timing approach (full daily dose 1-2 hours before training) works for some but produces less stable blood levels than split dosing

1. [1]Ziegler JB. Development of methandrostenolone. Strength & Health Magazine. 1960s.
2. [2]Kicman AT. Pharmacology of anabolic steroids. Br J Pharmacol. 2008;154(3):502-521.
3. [3]Methandrostenolone hepatotoxicity studies. Liver International.
4. [4]Friedl KE. Reappraisal of the health risks associated with high doses of oral and injectable androgenic steroids. NIDA Res Monogr. 1990.